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Abstract 
A near  infrared (NIR) method able to directly quantify the active content in 
pharmaceutical powder blends used for manufacturing meloxicam tablets, 
without any sample preparation, was developed and fully validated.  
To develop calibration models for the assay of meloxicam in powder blends for 
tableting, the NIR reflectance spectra of different meloxicam powder blends 
prepared according to a calibration protocol was analysed using different pre-
processing methods by partial last-square regression (PLS) and principal 
component regression (PCR).  
The best calibration model was found when partial last-square regression (PLS) 
was used as regression algorithm in association with Smoothing-Savitsky as 
pre-processing spectrum method.  The trueness, precision (repeatability and 
intermediate precision), accuracy, linearity and range of application of the 
developed NIR method were validated according to the International 
Conference of Harmonization (ICH) and Medicine European  Agency  (EMA) 
guidelines and found to be fit for its intended purpose. 
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Introduction 
The concept of Process Analytical Technology (PAT) was introduced by FDA, EMA and 
ICH in drug manufacturing guidance [1–3].  Near  Infrared  (NIR)  spectroscopy is an 
important component of a PAT toolbox and is a key technology for enabling rapid analysis 
of the manufacturing process of pharmaceutical tablets. Direct analysis of pharmaceutical 
powder blends or intact solid dosage forms is considered to be a very important goal for 
NIR Attributes (CQAs) as an analysis of pharmaceutical solids, with the increasing needs 
for on-line or at-line testing [4, 5]. 
As a PAT tool, Near Infrared (NIR) spectroscopy is extensively used to monitor such 
Critical Quality moisture content in the granules and crystal forms of a drug during the 
granulating-drying process [6, 7], compact hardness during the roller compaction process 
[8] and blend uniformity during the powder blending process [9, 10] because of its rapid 
and non-destructive process. The NIR spectrum of a powder sample reflects both 
chemical and physical information [11, 12].  
Thus, NIR spectroscopy can be used to perform quantitative determinations of specific 
compounds in complex matrices, like, for instance, a pharmaceutical powder blend for 
tableting. A NIR assay method is usually not performed in the “traditional” way like 
UVspectrometry or HPLC. The major step to  develop a  NIR assay  method is the 
calibration procedure for model development. Once a calibration is developed and 
favourable predictions are expected, they must be validated to be accepted for routine 
use. For external validation, independent sets of samples are needed. There are several 
validation parameters that must be determined in order to be consistent with the 
recommendations of the International Conference of Harmonisation (ICH) and with other 
guidelines: accuracy, precision (repeatability and intermediate precision), specificity, 
linearity and range of application [10, 11, 13]. 
Ensuring an appropriate calibration concentration range is one of the main limitations of 
NIR spectroscopy applications in quantitative applications in the pharmaceutical industrial 
environment. Concentration variability is necessary to guarantee the method’s robustness. 
A desirable range between 80% and 120% would be advantageous to improve the 
accuracy of the calibration. Several methods were proposed to set up a NIR-based 
calibration method: 
(i) The use of normal production tablets with development of samples which would 
normally be out of specification, in order to extend the concentration range. 
(ii) The use of laboratory-made samples, developed by changing the concentration of the 
components in the matrix. 
(iii) The use of laboratory samples with production samples, comprising granules, tablet 
cores and coated tablets, in order to include all sources of variation in the model [11–15]. 
The most frequent methods to construct the calibration set are the use of doped 
production samples (method of standard addition) and the use of laboratory-made 
samples. A number of papers compare the  methods and conclude that both methods 
produce similar results [11, 12]. 
The aim of this work was to develop and validate a NIR-chemometric method for the assay 
of meloxicam in powder blends for tableting, based on laboratory made samples, in order 
to be used for in-line/at-line meloxicam pharmaceutical process monitoring.    High-Throughput NIR-Chemometric Method for Meloxicam Assay  887 
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Results and Discussion 
The aim of our research was to develop a NIR-chemometric method suitable for the direct 
quantification of meloxicam in powder blends for tableting, without any sample preparation. 
To  ensure  appropriate quantitative results, the set of calibration samples has to be 
representative of the changes in the properties of samples that will be found in routine 
analysis. In general, the calibration set will contain an approximately balanced distribution 
of samples across the concentration domain and a considerable number of representative 
samples for each level of concentration of the substance of interest. The matrix of the 
calibration protocol was presented in Table 2.  
 
a 
 
b 
Fig. 1.  Reflectance spectrum of all calibration powder blends (a) and of the powder 
blends at three concentration levels (10%, 12.5%, 15%) of meloxicam (b) 888  I. Tomuta et al.:   
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Method development 
Spectra investigation. The development of a calibration model consisted in checking 
different spectral pre-treatments as well as their combination with different spectral ranges. 
Both the whole spectral range and specific spectral regions containing strong bands and 
different spectral pre-treatments were tested with a view to constructing the calibration 
models. The near infrared spectra of the calibration powder blends are shown in figure 1a. 
The spectra of the three fractions used in the calibration model are shown in Figure 1b. As 
shown in figure 1b, significant differences are present especially in the 7500–4000 cm
−1 
range of the spectrums. This region was used for model calibration.  
To make quantitative analysis using NIR spectroscopy, mathematical and statistical 
methods (chemometric methods and multivariate analysis) are required, which will extract 
the relevant information and reduce the  irrelevant information. Spectral interference 
parameters are calling for mathematical corrections, the so-called spectra pre-treatments, 
to reduce, eliminate or standardize their impact on the spectra. 
In this study, the model development consisted in checking different spectra pre-
treatments in combination with the whole spectra or different spectral regions containing 
strong bands of meloxicam. Multivariate calibration was then applied to chemometric 
approaches based on PLS and PCR regression. After designing the calibration model, its 
predictive ability was tested with the samples used during its development. The validation 
of the model was done using the cross-validation method, leaving out one sample at a 
time, and the predicted concentrations were compared with the known concentrations of 
the compounds in each sample. The RMSECV was used as a diagnostic test for 
examining the errors in the predicted concentrations because it indicates both precision 
and accuracy of predictions. It was calculated upon addition of each new factor to the PLS 
and PCR models. For each pre-processing method, the squared correlation coefficient, R
2, 
between actual known concentration and predicted concentration, was computed to 
evaluate the predictive ability of the model.  
Tab. 4.   Statistical parameters and numbers of principal components in the PCR 
method, without data pre-treatments, as well as after different spectra pre-
treatments 
Pre-treatment  Model  PC  
number 
RMSECV  RMSEP  R
2  Bias 
(a) None  PCR  6  0.3274  0,3571  0.9740  0.0250 
(b) Smoothing-Moving Average  PCR  4  0.3356  0.3554  0.9831  0.0254 
(c) Smoothing-SavitskyGolay  PCR  4  0.3270  0.3424  0.9841  0.0250 
(d) Unit Vector Normalization  PCR  5  0.5368  0.5606  0.9569  0.0347 
(e) Min/max normalization  PCR  5  0.5194  0.5721  0.9593  0.0293 
(f) Standard Normal Variate  PCR  5  0.6407  0.6671  0.9398  0.0298 
(g) NorisGrap first derivate  PCR  5  0.6279  0.6546  0.9408  0.0352 
(h) NorisGrap second derivate  PCR  5  0.3306  0.3622  0.9836  0.0045 
(i) Deresolve  PCR  4  0.3348  0.3504  0.9832  0.0252 
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The optimal number of factors was selected by the following criteria: the selected model is 
that with the smallest number of factors such that RMSECV for that model is not 
significantly greater than RMSECV for the model with one or more additional factors [14]. 
The NIR-chemometric model was developed taking into account all the samples of the 
three series of samples from the calibration matrix. The results obtained during the method 
development are presented in Tables 4 and 5 and Figures 2 and 3. 
Tab. 5.   Statistical parameters and numbers of the principal components in the PLS 
method, without data pre-treatments, as well as after different spectra pre-
treatments 
Pre-treatment  Model  PC  
number  RMSECV  RMSEP  R
2  Bias 
(a) None  PLS  5  0.39233  0.3966  0.9789  0.0707 
(b) Smoothing-Moving Aveage  PLS  4  0.40885  0.4702  0.9768  0.1127 
(c) Smoothing-SavitskyGolay  PLS  4  0.32453  0.3316  0.9889  0.0501 
(d) Unit Vector Normalization  PLS  4  0.55465  0.5755  0.9543  −0.0115 
(e) Min/max normalization  PLS  5  0.50516  0.5542  0.9616  0.0348 
(f) Standard Normal Variate  PLS  7  0.41884  0.4501  0.9744  0.0670 
(g) NorisGrap first derivate  PLS  6  0.59724  0.6202  0.9483  0.0121 
(h) NorisGrap second derivate  PLS  5  0.41767  0.4455  0.9742  0.0572 
(i) Deresolve  PLS  4  0.33095  0.3462  0.9826  0.0243 
 
Concerning the results, the R
2 values for the proposed models were greater than 0.98, in 
(b), (c), (h) and (i) PCR models and (c) and (i) PLS models. The lowest number of PCR 
factors was 4 for models (b), (c) and (i), and the lowest number of PLS factors was also 3 
for models (b), (c),  (d) and (1). Considering the RMSECV and bias for those models, 
together with the R
2 values and the number of factors, the (c) model, using the Smoothing-
Savitsky method, has been chosen as the best fitted model for meloxicam quantification in 
powder blends for tableting, using the PLS algorithm. 
Figure 2 shows the RMSECV plotted as a function of (a) PCR and (b) PLS factors for the 
quantification of meloxicam in powder blends  for  tableting  with different spectra pre-
processing methods.  
Based on the results presented in Table 4, 5 and Figure 2, the Smoothing - Savitsky pre-
treatment has been chosen as the best fitted model for meloxicam quantification, using the 
PLS algorithm and the optimal number of factors as 4. 
The plots of predicted concentration versus true concentration for meloxicam in powder 
blends for tableting are shown in Figure 3. The predicted values were obtained using the 
Smoothing-Savitsky pre-treatment method, PLS algorithm and 4 PLS factors chosen in the 
calibration of model.  
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b 
Fig. 2.   Plotting RMSECV vs. (a) number of PCR factors, (b) number of PLS factors 
Method validation 
The model predictive performance was evaluated with accuracy profiles computed on the 
external validation results. This approach is using tolerance intervals as statistical 
methodology that allows predicting a region of concentration where each future result has 
a probability to fall defined by the analyst [19]. The accuracy profile has the advantage of 
taking into account the total error, which is the sum of the trueness (systematic error) and 
precision (random error), and meets the ICH Q2 (R1) guideline requirements [20–22].  
Table 7 shows the ICH Q2 (R1) validation criteria of the developed method. The trueness 
of the method was evaluated by calculating the recovery. The recovery has satisfactory 
values for all three concentration levels (Table 6). The precision of the method was 
evaluated by calculating two parameters: repeatability and intermediate precision at the 
three concentration levels  in the  validation protocol. Both parameters had satisfactory 
values for all concentration levels (Table 6).    High-Throughput NIR-Chemometric Method for Meloxicam Assay  891 
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Fig. 3.   NIR predicted meloxicam concentration versus true meloxicam concentration, 
cross-validation 
 
Fig. 4.   Accuracy profile of the NIR method for the quantification of meloxicam in 
powder blends 
The linear profile of the prediction model is shown in Table 6 and Figure 5. The linear 
model was represented by plotting the calculated concentrations of the validation samples 
as a function of the introduced concentrations. The dashed limits on the graph correspond 
to the accuracy profile and the dotted curves represent the acceptance limits at ±15% 
expressed in the concentration unit. As seen in the figure, the R
2 value is 0.9956 and the 
slope is very close to 1, confirming the linearity of the  model for quantification of 
meloxicam in powder blends for tableting.  
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Tab. 6.   Validation results of the NIR method for meloxicam quantification in powder 
blends 
Trueness 
Concentration 
level  
(% meloxicam) 
Mean 
concentration 
(% meloxicam) 
Recovery (%) 
   
10.00  10.03  100.27     
12.50  12.60  100.80     
15.00  15.03  100.23     
Precision 
Concentration 
level 
(% meloxicam) 
Relative bias 
(%) 
Repeatability 
(RSD %) 
Intermediate 
precision 
(RSD %)   
10.00  0.2673  1.359  1.183   
12.50  0.7985  1.116  0.982   
15.00  0.2320  1.158  1.006   
Accuracy 
profile 
Concentration 
level  
(% meloxicam) 
Lower 
RelTol. Limit 
 (%) 
Upper RelTol. 
Limit 
(%) 
Lower 
acceptance 
limit (%) 
Upper 
acceptance 
limit (%) 
10.00  −3.022  3.557  −5  5 
12.50  −1.943  3.539  −5  5 
15.00  −2.564  3.028  −5  5 
Linearity 
Profile 
Concentration 
Lower Tol.  
Limit  
(% meloxicam) 
Upper Tol. 
Limit  
(% meloxicam) 
Lower 
acceptance 
limit  
(% meloxicam) 
Upper 
acceptance 
limit  
(% meloxicam) 
10  9.696  10.356  9.500  10.500 
12.5  12.254  12.945  11.875  13.125 
15  14.614  15.455  14.250  15.750 
 
 
Fig. 5.   Linearity profile of the NIR method for the quantification of meloxicam in powder 
blends 
y = 1.0016x + 0.0336
R² = 0.9956
9
10
11
12
13
14
15
16
9.5 10.5 11.5 12.5 13.5 14.5 15.5
M
e
a
s
u
r
e
d
 
c
o
n
c
e
n
t
r
a
t
i
o
n
(
(
%
 
m
e
l
o
x
i
c
a
n
 
i
n
 
p
o
w
d
e
r
 
b
l
e
n
d
)
Theoretical concentration (% meloxican in powder blend)
Linearity Profile  High-Throughput NIR-Chemometric Method for Meloxicam Assay  893 
Sci Pharm. 2011; 79: 885–898 
As shown in Table 6 and Figure 4, the accuracy of the method for the entire meloxicam 
concentration domain is good, because the β-expectation tolerance limits never exceed 
the ±15% acceptance limits. The best accuracy was obtained at the concentration level of 
12.5 % meloxicam in powder blend for tableting. 
Conclusions 
A near infrared method was  developed for the quantification of meloxicam in powder 
blends for tableting. Different calibration models were evaluated for the quantification of 
meloxicam in powder blends for tableting, ranging from 10–15%, using NIR-chemometic 
technique. Then, using the best calibration model, the method was fully validated 
according to the ICH guidance. The validation results showed good precision, trueness 
and accuracy for the determination of meloxicam in powder blends for tableting with 
contents ranging from 10–15% meloxicam in powder blend (coresponding to 80–120% 
active substance content).  
The proposed NIR method allows the active substance (meloxicam) content in 
pharmaceutical powder blends for tablet manufacturing to be determined with no sample 
preparation. In another research paper [24] the authors have shown that it is possible to 
directly predict from the NIR reflection spectrum the pharmaceutical properties of the same 
meloxicam powder blends, such as mean particle size, poly-dispersion index, angle of 
repose and the time of flow, without any sample preparation. 
Such quick NIR-chemometric methods can be used for on-line, in line or at line monitoring 
of the manufacturing process of meloxicam tablets and are helpful in achieving the goals 
of the process analytical technology (PAT) concept. 
Experimental 
Materials  
Meloxicam (Uquifa, Spain), isomalt (BENEO-Palatinit GmbH, Germany), microcrystalline 
cellulose (JRS Pharma, Germany), sodium starch glycolate  (JRS Pharma, Germany), 
silicon dioxide–Aerosil (RohmPharma Polymers, Germany), magnesium stearate (Union 
Derivan, Spain). 
Preparation of powder blends for NIR calibration 
The formula of the powder blends for the preparation of meloxicam tablets are presented 
in Table 1. 
In detail, meloxicam, isomalt, microcrystalline cellulose, and sodium starch glycolate were 
mixed using a planetary mixer (PRS type, Erweka, Germany) for 5 min. Magnesium 
stearate was added; the mixing was continued for 1 more minute. 
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Tab. 1.   Qualitative and quantitative formula of powder blends for tablet preparation 
  mg / tablet  % 
Meloxicam  15.00  12.50 
Isomalt  52.20  43.50 
Microcrystalline Cellulose PH 102  45  37.50 
Sodium starch glycolate  6  5.00 
Silicon dioxide  1.2  1.00 
Magnesium stearate  0.6  0.50 
   120.00   
 
Calibration and validation protocol 
An experimental protocol was followed for the calibration and validation steps in order to 
develop and to validate a robust near infrared model. This protocol included batches and 
days as sources of variability for the calibration as well as for the validation steps. Five 
concentration levels of active pharmaceutical ingredient (meloxicam) were evaluated 
(Table 2). 
Tab. 2.   Matrix of calibration and validation protocol 
Concentration level  Series 1  Series 2  Series 3 
Calibrat.  Validat.  Calibrat.  Validat.  Calibrat.  Validat. 
1  80%  1  4  1  4  1  4 
2  90%  1  0  1  0  1  0 
3  100%  1  4  1  4  1  4 
4  110%  1  0  1  0  1  0 
5  120%  1  4  1  4  1  4 
 
Calibration samples 
Laboratory batches of meloxicam powder blends for tablet preparation were manufactured 
according to the method previously described. The usual targeted formulation contains 
12.5% w/w meloxicam (15 mg/tablet). This formulation will be further considered as the 
100% active content formulation. For the calibration set, five laboratory batches containing 
10, 11.25, 12.50, 13.75 and 15%w/w meloxicam were also manufactured (corresponding 
to 80, 90, 100, 110 and 120% API formulations). The amount of microcrystalline cellulose 
was adjusted to give a 120 mg final weight for each tablet, as shown in Table 3. Three 
independent batch series of five concentration levels were manufactured. 
External validation samples 
New laboratory batches of meloxicam powder blends for tablets were manufactured for 
validation. The same formulations as for the calibration samples were manufactured at 
three concentration levels (levels 1, 3 and 5 from Table 3), corresponding to the 80, 100 
and 120% concentrations of the API formulations. Four independent batch series were 
manufactured for each concentration level.   High-Throughput NIR-Chemometric Method for Meloxicam Assay  895 
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Tab. 3.   Composition of calibration samples and external validation samples 
Concentration Levels  1
a,b  2
a  3
a,b  4
a  5
a,b 
80%  90%  100%  110%  120% 
Meloxicam (w/w)  10.00%  11.25%  12.50%  13.75%  15.00% 
Tablet composition (mg/tablet) 
Meloxicam  12  13.5  15  16.5  18 
Isomalt  55.2  53.7  52.2  50.7  49.2 
Microcrystalline Cellulose  45  45  45  45  45 
Sodium starch glycolate  6  6  6  6  6 
Silicon dioxide  1.2  1.2  1.2  1.2  1.2 
Magnesium stearate  0.6  0.6  0.6  0.6  0.6 
  120  120  120  120  120 
a calibration samples; 
b external validation samples. 
 
NIR-spectroscopic analysis 
The powder blend samples were analysed using a NIR model Antaris II FT-NIR Analyser 
(TermoElectron, SUA) in Reflectance Sampling configuration. Each reflectance spectrum 
was recorded using OMNIC software by integrating 32 scans taken from 11000 to 
4000cm
−1 at 8cm
−1 resolution.  
Model development 
Calibration and prediction 
The model with the biggest predictive potential was selected according to conventional 
classical criteria such as the R
2, the number of PLS factors, the Root Mean Square Error 
of Calibration (RMSEC) and the Root Mean Square Error of Estimation (RMSEE) [16]. 
Those parameters were calculated by the Unscrambler software package (Camo, 
Norway). The software allows  validating the models by full cross-validation. In this 
procedure, iterative calibrations were performed removing in turn each standard from the 
training set and then predicting the excluded sample with that calibration. 
Spectra preprocessing and regression methods 
The model was developed with various combinations of the mathematical pre-processing. 
The spectral pre-treatments tested with a view to  constructing  the calibration models 
included the first and second derivative, and the Standard Normal Variate (SNV). First and 
second spectral derivatives were obtained by applying the Savitzky–Golay algorithm to 11 
moving window points and a second-order polynomial. The influence of two standard 
regression methods, principal component regression (PCR) and partial least squares 
(PLS) regression, were also examined, selected because they were the most accurate in 
terms of model complexity and the number of samples used to build the calibrations. The 
optimal numbers of factors for  PCR and PLS were determined by a cross-validation 
procedure with groups of two spectra (each side of the sample being represented by a 
spectrum) [17, 18].  
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Method validation 
Once a calibration is developed and favourable predictions are expected, they must be 
validated to be accepted for routine use. Independent sets of samples are needed for 
external validation. There are several validation parameters that must be determined in 
order to be consistent with the recommendations of the International Conference of 
Harmonization (ICH) and with other guidelines: accuracy, precision (repeatability and 
intermediate precision), linearity and range of application. The validation was performed 
according to the strategy proposed by Hubert et al [20–23]. 
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